Elevai Labs Releases Initial Indications from Research Study For Androgenic Alopecia

A recent press release from Elevai Labs noted “encouraging data results” from a study conducted by its subsidiary, Elevai Skincare Inc. We don’t have the full details of the study, but it was mentioned in the press release that it is an ongoing study in which patients with androgenic alopecia were treated with Elevai Exosomes.

The Study

Participants in the study received treatments in the clinic and at home. The in-clinic treatment was Elevai empower™, a serum containing exosomes specifically for in-clinic use. The participants underwent scalp needling before the serum was applied. The at-home treatment was Elevai enfinity™, a topical treatment containing exosomes applied to balding areas of the scalp. 

The Results

According to the short press release, after 12 months, imaging showed a cessation of crown inflammation, reduced miniaturized hairs, and fewer hairs in the telogen (non-growing) phase.

This study is a foundation for Elevai’s ongoing research into their new hair and scalp care line, the Elevai S-Series Root Renewal System™. It integrates Elevai’s proprietary PREx™ technology alongside Yuva Bioscience’s Y100 mitochondrial technology. This system includes a shampoo, conditioner, and serum. 

Reflections

Although these statements are encouraging, we’ll need to wait for the actual data to be released before making any conclusions about the product’s effectiveness. We’ve previously written about Yuva Biosciences and its collaboration with Elevai Labs to create new pharmaceuticals and cosmetics for hair and skin. Yuva Biosciences has developed Y100, a compound that targets mitochondrial dysfunction.

Let us know in the comments what you think about these results so far. 

9 Comments

  1. Colum on September 6, 2024 at 5:06 pm

    Another “study” that’s only purpose is to secure more funding for those running the “study”

  2. Hasan on September 7, 2024 at 1:42 pm

    Where can I get to.order this from..

  3. rapanui on September 8, 2024 at 2:48 am

    I think that microneedling must be used very often in ecosome treatment

  4. gjg on September 8, 2024 at 12:18 pm

    Oh look, another company that’s managed to get 10 extra follicles. OMG!!!!! Wake me up in 10 years, maybe by then CRISPR or AI will have actually solved this. Until then, these are all money grabs. Stay strong, my cursed brothers.

  5. Paul Simpkins on September 8, 2024 at 3:36 pm

    Does this really mean anything?

    • Michael on September 19, 2024 at 6:15 pm

      Yep…another 5 years..

  6. Paul Simpkins on September 8, 2024 at 5:55 pm

    Does this really mean anything?

  7. Ahmed Bekeer on September 11, 2024 at 10:40 am

    Coegin Pharma announces Follicopeptide as the commercial ingredient brand name for FOL005
    Coegin Pharma’s INCI application for FOL005 was approved at the end of May 2024, and an INCI name was granted. This marked a significant milestone in the company’s preparations for the global launch of a product series for hair growth, as an INCI approval is essential for marketing cosmetic products globally. The company has since chosen to trademark the name and can now announce the commercial ingredient brand name “Follicopeptide”.
    https://news.bequoted.com/newsroom/coegin-pharma/pressreleases/coegin-pharma-announces-follicopeptide-as-the-commercial-ing-59408/

  8. Anna on September 15, 2024 at 11:29 pm

    Hello, thank you very creating this insightful blog and updating it regularly. May I ask when you think hair replication will be available for ordinary people, like in how many years? Thank you.

Leave a Comment





Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.